Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Signet Ring Adenocarcinoma of the Colon
Stage IIIB Colon Cancer
Stage IIIC Colon Cancer
Mucinous Adenocarcinoma of the Colon
Mucinous Adenocarcinoma of the Rectum
Recurrent Rectal Cancer
Signet Ring Adenocarcinoma of the Rectum
Stage IIIA Rectal Cancer
Stage IVA Colon Cancer
Recurrent Colon Cancer

Interventions: Drug: 6,8-bis(benzylthio)octanoic acid
Drug: fluorouracil
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2014-09-05

Last Posted Date: 2023-08-07

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 19

Registration Number: NCT02232152

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

Phase 1

Completed

Conditions: Metastatic Pancreatic Adenocarcinoma

Interventions: Drug: BBI608
Drug: Nab-paclitaxel
Drug: Oxaliplatin
Drug: Leucovorin
Drug: Gemcitabine
Drug: Irinotecan
Drug: MM-398
Drug: Fluorouracil

First Posted Date: 2014-09-04

Last Posted Date: 2023-11-18

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 139

Registration Number: NCT02231723

Locations: 🇺🇸
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Virginia Oncology Associates, Norfolk, Virginia, United States

and more 9 locations

Phase II Study of Albumin Bound Paclitaxel With 5-FU and CF as Second Line in Taxanes Naive Advanced Gastric Cancer

Phase 2

Conditions: Gastric Caner

Interventions: Drug: Albumin Bound Paclitaxel
Drug: 5-FU

First Posted Date: 2014-08-29

Last Posted Date: 2014-08-29

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 37

Registration Number: NCT02229045

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma

Phase 2

Completed

Conditions: Squamous Cell Carcinoma of Skin
Carcinoma, Squamous Cell

Interventions: Drug: Pegylated Interferon alpha-2b
Drug: Capecitabine
Drug: 5-FU

First Posted Date: 2014-08-15

Last Posted Date: 2022-10-07

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 8

Registration Number: NCT02218164

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma

Phase 2

Completed

Conditions: Resectable Prancreas Carcinoma

Interventions: Drug: Oxaliplatin
Drug: Gemcitabine
Drug: 5-Fluorouracil
Drug: Irinotecan
Drug: Natriumfolinate

First Posted Date: 2014-06-24

Last Posted Date: 2020-09-02

Lead Sponsor: Krankenhaus Nordwest

Target Recruit Count: 40

Registration Number: NCT02172976

Locations: 🇩🇪
Institute of Clinical Cancer Research (IKF), UCT - University Cancer Center, Frankfurt, Germany, Frankfurt, Germany

Treatment of Keloidscars With Intralesional Triamcinolone and 5-fluorouracil Injections-prospective, Randomized, Controlled Trial - Pilot Study

Phase 4

Completed

Conditions: Keloidscars

Interventions: Drug: Triamcinolone
Drug: 5-fluorouracil

First Posted Date: 2014-06-04

Last Posted Date: 2018-04-26

Lead Sponsor: Tampere University Hospital

Target Recruit Count: 50

Registration Number: NCT02155439

Locations: 🇫🇮
Tampere university hospital, Tampere, Finland

Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Metastatic Cancer
Toxicity

Interventions: Drug: Oxaliplatine
Drug: Folinic acid
Drug: Irinotecan
Drug: 5-FU

First Posted Date: 2014-05-21

Last Posted Date: 2022-07-28

Lead Sponsor: Institut Cancerologie de l'Ouest

Target Recruit Count: 72

Registration Number: NCT02143219

Locations: 🇫🇷
ICO Paul Papin, Angers, France
🇫🇷
CH Vendée, La Roche Sur Yon, France
🇫🇷
Centre Oscar Lambret, Lille, France

and more 3 locations

A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer

Phase 2

Terminated

Conditions: Colorectal Cancer

Interventions: Drug: 5-FU
Drug: Folinic acid
Drug: Bevacizumab
Drug: Oxaliplatin
Drug: Vanucizumab

First Posted Date: 2014-05-19

Last Posted Date: 2020-03-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 197

Registration Number: NCT02141295

Locations: 🇬🇧
Guys and St Thomas NHS Foundation Trust, Guys Hospital, London, United Kingdom
🇺🇸
Fresno cCare, Fresno, California, United States
🇺🇸
Oncology Hematology Care Inc, Cincinnati, Ohio, United States

and more 36 locations

Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer

Phase 2

Active, not recruiting

Conditions: Colon Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Leucovorin
Drug: Irinotecan
Drug: Bevacizumab

First Posted Date: 2014-05-14

Last Posted Date: 2023-09-14

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 100

Registration Number: NCT02138617

Locations: 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
IU Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Carolina Healthcare Systems, Charlotte, North Carolina, United States

and more 4 locations

Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions

Phase 3

Completed

Conditions: High-grade Squamous Intraepithelial Lesion
HIV Infection
Anal Cancer
Human Papilloma Virus Infection

Interventions: Drug: imiquimod
Drug: fluorouracil
Other: laboratory biomarker analysis
Device: infrared photocoagulation therapy
Device: thermal ablation therapy
Device: laser therapy
Other: clinical observation

First Posted Date: 2014-05-12

Last Posted Date: 2024-07-26

Lead Sponsor: AIDS Malignancy Consortium

Target Recruit Count: 4446

Registration Number: NCT02135419

Locations: 🇺🇸
Anal Dysplasia Clinic MidWest, Chicago, Illinois, United States
🇺🇸
The Polyclinic, Seattle, Washington, United States
🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States

and more 22 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy